Most Read Articles
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
17 Oct 2019
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Roshini Claire Anthony, 2 days ago

The addition of pertuzumab to a trastuzumab-docetaxel regimen in the neoadjuvant setting improved total pathological complete response (tpCR) rates in Asian women with early or locally advanced ERBB2-positive breast cancer, according to the phase III PEONY trial from China.

Pearl Toh, 09 Sep 2019
Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.

Ilaprazole not inferior to rabeprazole in treatment of duodenal ulcer

06 Oct 2019

The efficacy of ilaprazole 5 mg appears to be on a par with rabeprazole 10 mg in treating duodenal ulcer, a study has shown. In addition, there is a dose-effect relationship between 5- and 10-mg ilaprazole.

In this double-blind, parallel, randomized study, patients aged >18 years with at least one endoscopically confirmed active nonmalignant duodenal ulcer received either rabeprazole 10 mg or ilaprazole 5/10 mg for 4 weeks. Ulcer healing was characterized by resolution from active to scarring stage.

The investigators assessed symptoms relief using a graded score and evaluated the safety and tolerability of these study drugs based on clinical assessments.

In total, 390 patients completed the study. Duodenal ulcer was successfully healed in 75.38 percent of patients in the rabeprazole 10-mg group, 77.86 percent in the ilaprazole 5-mg group and 83.72 percent in the ilaprazole 10-mg group after 4 weeks of treatment.

The 4-week healing rate difference between rabeprazole 10 mg and ilaprazole 5 mg was 2.58 percent (95 percent CI, –7.79 percent to 12.74 percent), showing the noninferiority of the latter. In logistic regression analysis, ilaprazole 10 mg was superior to ilaprazole 5 mg at week 2 (odds ratio, 1.92, 1.02–3.59; p=0.04).

Eighty percent of patients became asymptomatic after treatment. All three drug groups showed comparable efficacy and safety profile at the dosages administered.

“Ilaprazole is a kind of benzimidazole proton-pump inhibitor, which was confirmed efficacious and safe in treatment of duodenal ulcer,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
17 Oct 2019
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Roshini Claire Anthony, 2 days ago

The addition of pertuzumab to a trastuzumab-docetaxel regimen in the neoadjuvant setting improved total pathological complete response (tpCR) rates in Asian women with early or locally advanced ERBB2-positive breast cancer, according to the phase III PEONY trial from China.

Pearl Toh, 09 Sep 2019
Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.